Genmab — Oktober 2017
-
J&J Halts Sirukumab Development, Talacotuzumab Trial
Johnson & Johnson said today it has ended development of the rheumatoid arthritis candidate sirukumab, and halted a Phase II/III trial of the acute myeloid leukemia (AML) candidate talacotuzumab—both of which the pharma giant had touted as potential blockbusters just five months ago
GEN - Genetic Engineering and Biotechnology News (www.genengnews.com)
-
Nyt midt i det hele
https://clinicaltrials.gov/ct2/show/NCT03311828?term=NCT03311828&rank=1 -
God morgen.

-
God morgen, ville være fantastisk med en rebound!

-
der er nok at købe af
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
